Global E-Health Forum - Hamburg 2011

11 - 13 October 2011, Hamburg, Germany.
Improving the quality of healthcare, increasing the efficiency of the systems and ensuring patient empowerment - these are the common goals worldwide when discussing the necessary transformation of the systems in order to guarantee a sustainable healthcare delivery in the future. The Global E-Health Forum - Hamburg 2011 will represent major stakeholders involved in designing personalized healthcare.

"E-Health is increasingly seen as a key enabler for this transformation," so Ljubisav Matejevic, founder and honorary chairman of the Global E-Health Forum. "And as a key enabler for the evolution process towards personalized healthcare. Healthcare that is proactive, instead of reactive, gives the patients the opportunity and the responsibility to become more involved in their own health. The ultimate goal will be to shape preventive and diagnostic care to match each person's unique characteristics."

The initiators of the Global E-Health Forum - Hamburg Chamber of Commerce, IBM and ICC - have developed this platform to discuss e-health strategies, best practices and new services/patient-centric approaches in a global context. While the main target groups consist of CEOs, CIOs and CFOs of hospitals and clinics, the comprehensive program will also attract representatives from governmental bodies, health insurance organizations, service providers, influencers from hospital and health management associations as well as representatives from universities/research institutes. Canada supports the Global E-Health Forum - Hamburg 2011 as partner country.

The first two conference days will feature speakers from all over the globe:

  • Richard C. Alvarez, President and Chief Executive Officer of Canada Health Infoway, with "Transforming Healthcare in Canada through E-Health"
  • Prof. WEN Ze Huai, (M. D.), Key Unit of Methodology in Clinical Research, Guangdong Traditional Chinese Medicine International Clinical Research Center, Research Center Guangdong Academy of Chinese Medical Sciences, with "Designing Personalized Healthcare for Integrated Medicine by Using Information Technology"
  • Dr. Eric M. Liederman, Director of Medical Informatics, The 45 Permanente Medical Group (USA), with "Balancing Privacy Protection with Patient Care"
  • Prof. Dr. Roland Eils, Division Head "Theoretical Bioinformatics", German Cancer Research Center (DKFZ) and Manuela Mueller-Gerndt, Healthcare Leader, IMT Germany, Smarter Healthcare, IBM Deutschland GmbH with "Oncology as a Key Driver for Cancer Research and Individualized Medicine"
  • Chai Chuah, National Director, National Health Board Business Unit, New Zealand Ministry of Health, with "Sustainable Personalized Healthcare - Challenges and Opportunities"

Their strategy presentations and case studies will be complemented by discussion forums, workshops and an exhibition of solution providers. During the evening reception at the U.S. Consulate General on October 11, there will be manifold opportunity of knowledge and experience exchange as well as networking. The third day is dedicated to various breakout sessions and guided tours at different locations (among others hospitals) targeting the individual information needs of special interest groups. The third day is dedicated to guided tours of different hospitals and clinics in Hamburg, three of them being Asklepios clinics. The Asklepios Hospital Group renewed its cooperation partnership with the Global E-Health Forum.

For further information and registration, please visit:
http://www.global-ehealth-forum.com

Most Popular Now

New strategy to treat Parkinson's disease

Northwestern Medicine scientists have used patient-derived neurons to develop and test a new strategy to treat Parkinson's disease by mitigating the effects of harmful ge...

AI could offer warnings about serious side effects…

The more medications a patient takes, the greater the likelihood that interactions between those drugs could trigger negative side effects, including long-term organ dama...

OPKO and Pfizer announce positive Phase 3 top-line…

OPKO Health Inc. (NASDAQ: OPK) and Pfizer Inc. (NYSE: PFE) announced that the global Phase 3 trial evaluating somatrogon dosed once-weekly in pre-pubertal children with g...

Trastuzumab deruxtecan granted FDA Priority Review…

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics Lice...

The Bristol-Myers Squibb-Pfizer Alliance and Fitbi…

The Bristol-Myers Squibb-Pfizer Alliance and Fitbit announced at the TIME 100 Health Summit in New York that they are working together to help drive timely diagnosis of a...

Nplate® (romiplostim) now approved for earlier use…

Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate® (romiplostim...

Bayer launches LifeHub UK focused on artificial in…

Bayer launched LifeHub UK to accelerate and optimize disease detection and data-driven drug discovery by developing artificial-intelligence-enabled imaging solutions. The...

Novartis announces that Jakavi® (ruxolitinib) meet…

Novartis today announced positive topline results from the Phase III REACH2 study evaluating Jakavi® (ruxolitinib) in patients with steroid-refractory acute graft-versus-...

Amgen recommends rejection of 'mini-tender' offer …

Amgen (NASDAQ:AMGN) today announced that it has been notified of an unsolicited "mini-tender" offer dated Oct. 11, 2019, made by TRC Capital Corporation, a private Canadi...

Antibody-based eye drops show promise for treating…

Researchers at the University of Illinois at Chicago are the first to identify the presence of a specific type of antibody, called anti-citrullinated protein autoantibodi...

First entirely digital clinical trial encourages p…

As little as a daily ping on your phone can boost physical activity, researchers from the Stanford University School of Medicine and their collaborators report in a new s...

Abbott and Omada Health partner to offer integrate…

Abbott (NYSE: ABT) and Omada Health announced today they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) ...